Related Experiment Video
Updated: Apr 16, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
Mitesh J Borad1, Gregory J Gores, Lewis R Roberts
1aDivision of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona bDepartment of Molecular Medicine cDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Purpose Of Review:
This review will cover the role of the fibroblast growth factor pathway in the pathogenesis, targeted therapy potential and prognostic value in patients with cholangiocarcinoma (CCA).
Recent Findings:
Recent studies that have identified fibroblast growth factor receptor 2 (FGFR2) fusions, prognostic implications of FGFR2 fusions, treatment strategies that target FGFR2 in CCA and future directions for understanding and targeting the FGFR2 pathway in this disease, will be discussed.
Summary:
Understanding the role of the FGFR2 pathway as a disease pathogenetic mechanism and the ability to develop targeted therapies and diagnostics surrounding this concept are critical elements toward developing novel targeted approaches in CCA.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Introduction to Fibroblasts
Abnormal Proliferation

